{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:59:07Z","timestamp":1791572347623,"version":"4.3.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["312878\/2022-2"],"award-info":[{"award-number":["312878\/2022-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10822-025-00712-2","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:52:42Z","timestamp":1764730362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multitarget-directed ligands in Alzheimer\u2019s disease: identification of AChE and BACE1 inhibitors by in silico approaches"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-7673","authenticated-orcid":false,"given":"Raissa Alves","family":"da Concei\u00e7\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-8650","authenticated-orcid":false,"given":"Maria Let\u00edcia de Castro","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-405X","authenticated-orcid":false,"given":"Alessandra Mendon\u00e7a Teles","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"712_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2021","unstructured":"Breijyeh Z, Karaman R (2021) Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules 25:1\u201328. https:\/\/doi.org\/10.3390\/molecules25245789","journal-title":"Molecules"},{"key":"712_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Leon MJ, Frisoni GB, Salloway S et al (2016) Alzheimer\u2019s disease. Lancet 388:505\u2013517. https:\/\/doi.org\/10.1016\/S0140-6736(15)01124-1","journal-title":"Lancet"},{"key":"712_CR3","unstructured":"ADI. World Alzheimer Report. Int Alzheimer\u2019s Dis 2023. https:\/\/www.alzint.org\/u\/World-Alzheimer-Report-2023.pdf (Accessed 28 Jan 2021)."},{"key":"712_CR4","unstructured":"WHO. World failing to address dementia challenge. World Heal Organ 2021. https:\/\/www.who.int\/news\/item\/02-09-2021-world-failing-to-address-dementia-challenge."},{"issue":"9533","key":"712_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368(9533):387\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(06)69113-7","journal-title":"Lancet"},{"key":"712_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ (2001) Alzheimer\u2019s disease: genes, proteins, and therapy. Physiol Rev 81:741\u2013766","journal-title":"Physiol Rev"},{"key":"712_CR7","unstructured":"Alzheimer\u2019s Association. Medications for memory, cognition and dementia-related behaviors 2025. https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/medications-for-memory#Types of drugs (Accessed 24 Oct 2025)."},{"key":"712_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hast.1264","volume":"51","author":"LM Fleck","year":"2021","unstructured":"Fleck LM (2021) Alzheimer\u2019s and Aducanumab: unjust profits and false hopes. Hastings Cent Rep 51:9\u201311. https:\/\/doi.org\/10.1002\/hast.1264","journal-title":"Hastings Cent Rep"},{"key":"712_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/1389450121999200819144544","volume":"22","author":"NFF Pirolla","year":"2021","unstructured":"Pirolla NFF, Batista VS, Viegas FPD, Gontijo VS, Mccarthy CR Jr, CV, et al (2021) Alzheimer\u2019s disease: related targets, synthesis of available drugs, bioactive compounds under development, and promising results obtained from multi-target approaches. Curr Drug Targets 22:505\u2013538. https:\/\/doi.org\/10.2174\/1389450121999200819144544","journal-title":"Curr Drug Targets"},{"key":"712_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","volume":"50","author":"A Verger","year":"2023","unstructured":"Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D et al (2023) FDA approval of lecanemab: the real start of widespread amyloid PET use? \u2014 the EANM neuroimaging committee perspective. Eur J Nucl Med Mol Imaging 50:1553\u20131555. https:\/\/doi.org\/10.1007\/s00259-023-06177-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"712_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","volume":"62","author":"E Proschak","year":"2019","unstructured":"Proschak E, Stark H, Merk D (2019) Polypharmacology by design: a medicinal chemist\u2019s perspective on multitargeting compounds. J Med Chem 62:420\u2013444. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00760","journal-title":"J Med Chem"},{"key":"712_CR12","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","volume":"62","author":"J Zhou","year":"2019","unstructured":"Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W et al (2019) Rational design of multitarget-directed ligands: strategies and emerging paradigms. J Med Chem 62:8881\u20138914. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00017","journal-title":"J Med Chem"},{"issue":"7","key":"712_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","volume":"41","author":"O Benek","year":"2020","unstructured":"Benek O, Korabecny J, Soukup O (2020) A perspective on multi-target drugs for Alzheimer\u2019s disease. Trends Pharmacol Sci 41(7):434\u2013445. https:\/\/doi.org\/10.1016\/j.tips.2020.04.008","journal-title":"Trends Pharmacol Sci"},{"key":"712_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.chembiol.2003.09.002","volume":"10","author":"AC Anderson","year":"2003","unstructured":"Anderson AC (2003) The process of structure-based drug design. Chem Biol 10:787\u2013797. https:\/\/doi.org\/10.1016\/j.chembiol.2003.09.002","journal-title":"Chem Biol"},{"key":"712_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules200713384","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD (2015) Molecular docking and structure-based drug design strategies. Molecules. https:\/\/doi.org\/10.3390\/molecules200713384","journal-title":"Molecules"},{"key":"712_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.drudis.2006.05.012","volume":"11","author":"G Klebe","year":"2006","unstructured":"Klebe G (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11:580\u2013594. https:\/\/doi.org\/10.1016\/j.drudis.2006.05.012","journal-title":"Drug Discov Today"},{"key":"712_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113705","volume":"224","author":"VT Sabe","year":"2021","unstructured":"Sabe VT, Ntombela T, Jhamba LA, Maguire GEM, Govender T, Naicker T et al (2021) Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: a review. Eur J Med Chem 224:113705. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113705","journal-title":"Eur J Med Chem"},{"key":"712_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1021\/ci200617d","volume":"52","author":"A Hamza","year":"2012","unstructured":"Hamza A, Wei N-N, Zhan C-G (2012) Ligand-based virtual screening approach using a new scoring function. J Chem Inf Model 52:963\u2013974. https:\/\/doi.org\/10.1021\/ci200617d","journal-title":"J Chem Inf Model"},{"key":"712_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"SY Yang","year":"2010","unstructured":"Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15:444\u2013450. https:\/\/doi.org\/10.1016\/j.drudis.2010.03.013","journal-title":"Drug Discov Today"},{"key":"712_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/minf.201000061","volume":"29","author":"A Tropsha","year":"2010","unstructured":"Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. Mol Inform 29:476\u2013488. https:\/\/doi.org\/10.1002\/minf.201000061","journal-title":"Mol Inform"},{"key":"712_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113492","volume":"221","author":"JPS Ferreira","year":"2021","unstructured":"Ferreira JPS, Albuquerque HMT, Cardoso SM, Silva AMS, Silva VLM (2021) Dual-target compounds for Alzheimer\u2019s disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Eur J Med Chem 221:113492. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113492","journal-title":"Eur J Med Chem"},{"key":"712_CR22","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.2174\/1568026623666230811113231","volume":"23","author":"P Banjare","year":"2023","unstructured":"Banjare P, Matore BW, Murmu A, Kumar V, Singh J, Roy PP (2023) In silico strategy: a promising implement in the development of multitarget drugs against neurodegenerative diseases. Curr Top Med Chem 23:2765\u20132791","journal-title":"Curr Top Med Chem"},{"key":"712_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/1567205054367838","volume":"2","author":"C Ballard","year":"2005","unstructured":"Ballard C, Greig N, Guillozet-Bongaarts A, Enz A, Darvesh S (2005) Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2:307\u2013318. https:\/\/doi.org\/10.2174\/1567205054367838","journal-title":"Curr Alzheimer Res"},{"key":"712_CR24","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.3390\/molecules17089529","volume":"17","author":"SD De Souza","year":"2012","unstructured":"De Souza SD, De Souza AMT, De Sousa ACC, Sodero ACR, Cabral LM, Albuquerque MG et al (2012) Hologram QSAR models of 4-[(diethylamino)methyl]-phenol inhibitors of acetyl\/butyrylcholinesterase enzymes as potential anti-alzheimer agents. Molecules 17:9529\u20139539. https:\/\/doi.org\/10.3390\/molecules17089529","journal-title":"Molecules"},{"key":"712_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108265","volume":"179","author":"JL Sussman","year":"2020","unstructured":"Sussman JL, Silman I (2020) Computational studies on cholinesterases: strengthening our understanding of the integration of structure, dynamics and function. Neuropharmacology 179:108265. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108265","journal-title":"Neuropharmacology"},{"key":"712_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21577\/1984-6835.20200133","volume":"13","author":"PN Goulart","year":"2021","unstructured":"Goulart PN, Caruso L, Nadur NF, Franco DP, K\u00fcmmerle AE, Lacerda RB (2021) Butyrylcholinesterase\u2013BuChE: a potential target for development of drugs for Alzheimer\u2019s disease treatment. Rev Virtual Quim 13:90\u2013126. https:\/\/doi.org\/10.21577\/1984-6835.20200133","journal-title":"Rev Virtual Quim"},{"key":"712_CR27","doi-asserted-by":"publisher","first-page":"10282","DOI":"10.1021\/jm300871x","volume":"55","author":"J Cheung","year":"2012","unstructured":"Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J et al (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 55:10282\u201310286. https:\/\/doi.org\/10.1021\/jm300871x","journal-title":"J Med Chem"},{"key":"712_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159x11311030006","volume":"11","author":"MB Colovic","year":"2013","unstructured":"Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM (2013) Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 11:315\u2013335. https:\/\/doi.org\/10.2174\/1570159x11311030006","journal-title":"Curr Neuropharmacol"},{"key":"712_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL et al (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15:565\u2013581. https:\/\/doi.org\/10.1038\/s41582-019-0244-7","journal-title":"Nat Rev Neurol"},{"key":"712_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2020.02.001","author":"H Hampel","year":"2020","unstructured":"Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N et al (2020) The \u03b2-secretase BACE1 in Alzheimer\u2019s disease. Biol Psych. https:\/\/doi.org\/10.1016\/j.biopsych.2020.02.001","journal-title":"Biol Psych"},{"key":"712_CR31","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1021\/bi0498252","volume":"43","author":"L Hong","year":"2004","unstructured":"Hong L, Tang J (2004) Flap position of free Memapsin 2 (\u03b2-Secretase), a model for flap opening in aspartic protease catalysis. Biochemistry 43:4689\u20134695. https:\/\/doi.org\/10.1021\/bi0498252","journal-title":"Biochemistry"},{"key":"712_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3233\/JAD-150834","volume":"50","author":"S Eketj\u00e4ll","year":"2016","unstructured":"Eketj\u00e4ll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, F\u00e4lting J et al (2016) AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J Alzheimers Dis 50:1109\u20131123. https:\/\/doi.org\/10.3233\/JAD-150834","journal-title":"J Alzheimers Dis"},{"key":"712_CR33","doi-asserted-by":"publisher","first-page":"P1623","DOI":"10.1016\/j.jalz.2018.07.213","volume":"14","author":"SY Lynch","year":"2018","unstructured":"Lynch SY, Kaplow J, Zhao J, Dhadda S, Luthman J, Albala B (2018) Elenbecestat, E2609, a Bace inhibitor: results from a phase-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer\u2019s disease. Alzheimers Dement 14:P1623. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.213","journal-title":"Alzheimers Dement"},{"key":"712_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201809316","volume":"10","author":"U Neumann","year":"2018","unstructured":"Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez M, Huledal G, Kolly C et al (2018) The BACE -1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease. EMBO Mol Med 10:1\u201318. https:\/\/doi.org\/10.15252\/emmm.201809316","journal-title":"EMBO Mol Med"},{"key":"712_CR35","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","volume":"59","author":"JD Scott","year":"2016","unstructured":"Scott JD, Li SW, Brunskill APJ, Chen X, Cox K, Cumming JN et al (2016) Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-dioxide derivative Verubecestat (MK-8931)-a \u03b2-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer\u2019s disease. J Med Chem 59:10435\u201310450. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00307","journal-title":"J Med Chem"},{"key":"712_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0415-6","volume":"10","author":"M Timmers","year":"2018","unstructured":"Timmers M, Streffer JR, Russu A, Tominaga Y, Shimizu H, Shiraishi A et al (2018) Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled study. Alzheimers Res Ther 10:1\u201318. https:\/\/doi.org\/10.1186\/s13195-018-0415-6","journal-title":"Alzheimers Res Ther"},{"key":"712_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2018.00178","volume":"6","author":"JRM Coimbra","year":"2018","unstructured":"Coimbra JRM, Marques DFF, Baptista SJ, Pereira CMF, Moreira PI, Dinis TCP et al (2018) Highlights in BACE1 inhibitors for Alzheimer\u2019s disease treatment. Front Chem 6:1\u201310. https:\/\/doi.org\/10.3389\/fchem.2018.00178","journal-title":"Front Chem"},{"key":"712_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","volume":"33","author":"B Das","year":"2019","unstructured":"Das B, Yan R (2019) A close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment. CNS Drugs 33:251\u2013263. https:\/\/doi.org\/10.1007\/s40263-019-00613-7","journal-title":"CNS Drugs"},{"key":"712_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1570159x18666200503023323","volume":"19","author":"M Hrabinova","year":"2021","unstructured":"Hrabinova M, Pejchal J, Kucera T, Jun D, Schmidt M, Soukup O (2021) Is it the twilight of BACE1 inhibitors? Curr Neuropharmacol 19:61\u201377. https:\/\/doi.org\/10.2174\/1570159x18666200503023323","journal-title":"Curr Neuropharmacol"},{"key":"712_CR40","unstructured":"ALZFORUM. Give BACE Inhibitors a second chance\u202f? 2023. https:\/\/www.alzforum.org\/news\/conference-coverage\/give-bace-inhibitors-second-chance (accessed April 4, 2025)."},{"key":"712_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"P-P Liu","year":"2019","unstructured":"Liu P-P, Xie Y, Meng X-Y, Kang J-S (2019) History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Signal Transduct Target Ther 4:1\u201322. https:\/\/doi.org\/10.1038\/s41392-019-0063-8","journal-title":"Signal Transduct Target Ther"},{"key":"712_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01911-3","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-01911-3","journal-title":"Signal Transduct Target Ther"},{"key":"712_CR43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"NC Inestrosa","year":"1996","unstructured":"Inestrosa NC, Alvarez A, P\u00e9rez CA, Moreno RD, Vicente M, Linker C et al (1996) Acetylcholinesterase accelerates assembly of amyloid-\u03b2-peptides into Alzheimer\u2019s fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881\u2013891. https:\/\/doi.org\/10.1016\/S0896-6273(00)80108-7","journal-title":"Neuron"},{"key":"712_CR44","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1523\/jneurosci.18-09-03213.1998","volume":"18","author":"A Alvarez","year":"1998","unstructured":"Alvarez A, Alarc\u00f3n R, Opazo C, Campos EO, Mu\u00f1oz FJ, Calder\u00f3n FH et al (1998) Stable complexes involving acetylcholinesterase and amyloid-\u03b2 peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer\u2019s fibrils. J Neurosci 18:3213\u20133223. https:\/\/doi.org\/10.1523\/jneurosci.18-09-03213.1998","journal-title":"J Neurosci"},{"key":"712_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2020.107355","volume":"88","author":"V Kumar","year":"2020","unstructured":"Kumar V, Saha A, Roy K (2020) In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer\u2019s disease. Comput Biol Chem 88:107355. https:\/\/doi.org\/10.1016\/j.compbiolchem.2020.107355","journal-title":"Comput Biol Chem"},{"key":"712_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1046\/j.0022-3042.2002.00770.x","volume":"80","author":"U Bodendorf","year":"2002","unstructured":"Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH et al (2002) Expression of human \u03b2-secretase in the mouse brain increases the steady-state level of \u03b2-amyloid. J Neurochem 80:799\u2013806. https:\/\/doi.org\/10.1046\/j.0022-3042.2002.00770.x","journal-title":"J Neurochem"},{"key":"712_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Y Luo","year":"2001","unstructured":"Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al (2001) Mice deficient in BACE1, the Alzheimer\u2019s \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation. Nat Neurosci 4:231\u2013232. https:\/\/doi.org\/10.1038\/85059","journal-title":"Nat Neurosci"},{"key":"712_CR48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1084\/jem.20171831","volume":"215","author":"X Hu","year":"2018","unstructured":"Hu X, Das B, Hou H, He W, Yan R (2018) BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J Exp Med 215:927\u2013940. https:\/\/doi.org\/10.1084\/jem.20171831","journal-title":"J Exp Med"},{"key":"712_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nm0103-3","volume":"9","author":"L Yang","year":"2003","unstructured":"Yang L, Lindholm K, Yan R, Citron M, Xia W, Yang X et al (2003) Elevated \u03b2 -secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9:3\u20134","journal-title":"Nat Med"},{"key":"712_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2217\/pme-2016-0033","volume":"13","author":"PR Manzine","year":"2016","unstructured":"Manzine PR, Souza MdaS, Cominetti MR (2016) BACE1 levels are increased in plasma of Alzheimer\u2019s disease patients compared with matched cognitively healthy controls. Per Med 13:531\u2013540. https:\/\/doi.org\/10.2217\/pme-2016-0033","journal-title":"Per Med"},{"key":"712_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22094688","volume":"22","author":"MM Salman","year":"2021","unstructured":"Salman MM, Al-Obaidi Z, Kitchen P, Loreto A, Bill RM, Wade-Martins R (2021) Advances in applying computer-aided drug design for neurodegenerative diseases. Int J Mol Sci 22:1\u201322. https:\/\/doi.org\/10.3390\/ijms22094688","journal-title":"Int J Mol Sci"},{"key":"712_CR52","first-page":"334","volume":"66","author":"G Sliwoski","year":"2014","unstructured":"Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Computational methods in drug discovery. Comput Methods Drug Discov 66:334\u2013395","journal-title":"Comput Methods Drug Discov"},{"key":"712_CR53","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.2174\/1568026618666180101163651","volume":"17","author":"T Usha","year":"2018","unstructured":"Usha T, Shanmugarajan D, Goyal AK, Kumar CS, Middha SK (2018) Recent updates on computer-aided drug discovery: time for a paradigm shift. Curr Top Med Chem 17:3296\u20133307. https:\/\/doi.org\/10.2174\/1568026618666180101163651","journal-title":"Curr Top Med Chem"},{"key":"712_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26082193","volume":"26","author":"P Cruz-vicente","year":"2021","unstructured":"Cruz-vicente P, Silvestre S, Gallardo E (2021) Alzheimer and Parkinson diseases: in-silico approaches. Molecules 26:1\u201328","journal-title":"Molecules"},{"key":"712_CR55","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719\u20132740. https:\/\/doi.org\/10.1021\/jm901137j","journal-title":"J Med Chem"},{"key":"712_CR56","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell JB, Nissink JWM (2018) Seven year itch: pan-assay interference compounds (PAINS) in 2017\u2013utility and limitations. ACS Chem Biol 13:36\u201344. https:\/\/doi.org\/10.1021\/acschembio.7b00903","journal-title":"ACS Chem Biol"},{"key":"712_CR57","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1016\/j.apsb.2021.02.023","volume":"11","author":"J Sun","year":"2021","unstructured":"Sun J, Zhong H, Wang K, Li N, Chen L (2021) Gains from no real PAINS: where \u2018fair trial strategy\u2019 stands in the development of multi-target ligands. Acta Pharm Sin B 11:3417\u20133432. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.023","journal-title":"Acta Pharm Sin B"},{"key":"712_CR58","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.4155\/fmc-2018-0116","volume":"10","author":"C Stork","year":"2018","unstructured":"Stork C, Kirchmair J (2018) Pain(s) relievers for medicinal chemists: how computational methods can assist in hit evaluation. Future Med Chem 10:1533\u20131535. https:\/\/doi.org\/10.4155\/fmc-2018-0116","journal-title":"Future Med Chem"},{"key":"712_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105740","volume":"220","author":"PP Parvatikar","year":"2023","unstructured":"Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R et al (2023) Artificial intelligence: machine learning approach for screening large database and drug discovery. Antiviral Res 220:105740. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105740","journal-title":"Antiviral Res"},{"key":"712_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules23081899","volume":"23","author":"T Pantsar","year":"2018","unstructured":"Pantsar T, Poso A (2018) Binding affinity via docking: fact and fiction. Molecules 23:1\u201311. https:\/\/doi.org\/10.3390\/molecules23081899","journal-title":"Molecules"},{"key":"712_CR61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrd745","volume":"1","author":"MA Miller","year":"2002","unstructured":"Miller MA (2002) Chemical database techniques in drug discovery. Nat Rev Drug Discov 1:220\u2013227. https:\/\/doi.org\/10.1038\/nrd745","journal-title":"Nat Rev Drug Discov"},{"key":"712_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A et al (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"key":"712_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.132979","volume":"1262","author":"SK Shrivastava","year":"2022","unstructured":"Shrivastava SK, Nivrutti AA, Bhardwaj B, Waiker DK, Verma A, Tripathi PN et al (2022) Drug reposition-based design, synthesis, and biological evaluation of dual inhibitors of acetylcholinesterase and \u03b2-secretase for treatment of Alzheimer\u2019s disease. J Mol Struct 1262:132979. https:\/\/doi.org\/10.1016\/j.molstruc.2022.132979","journal-title":"J Mol Struct"},{"key":"712_CR64","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"S Kim","year":"2021","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S et al (2021) PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 49:D1388\u2013D1395. https:\/\/doi.org\/10.1093\/nar\/gkaa971","journal-title":"Nucleic Acids Res"},{"key":"712_CR65","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.30492\/ijcce.2022.554082.5347","volume":"42","author":"S Roosta","year":"2023","unstructured":"Roosta S, Hashemianzadeh SM, Gharaghani S, Mohammad Hossein KJ (2023) The interaction of a novel drug with \u03b2-secretase-1 and acetylcholinesterase: a computational investigation from both dynamics and thermodynamics viewpoints. Iran J Chem Chem Eng 42:1447\u20131462. https:\/\/doi.org\/10.30492\/ijcce.2022.554082.5347","journal-title":"Iran J Chem Chem Eng"},{"key":"712_CR66","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1021\/acschemneuro.7b00416","volume":"9","author":"RM Vitale","year":"2018","unstructured":"Vitale RM, Rispoli V, Desiderio D, Sgammato R, Thellung S, Canale C et al (2018) In silico identification and experimental validation of novel anti-Alzheimer\u2019s multitargeted ligands from a marine source featuring a \u201c2-aminoimidazole plus aromatic group\u201d scaffold. ACS Chem Neurosci 9:1290\u20131303. https:\/\/doi.org\/10.1021\/acschemneuro.7b00416","journal-title":"ACS Chem Neurosci"},{"key":"712_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107861","volume":"226","author":"XY Mao","year":"2021","unstructured":"Mao XY, Yin XX, Guan QW, Xia QX, Yang N, Zhou HH et al (2021) Dietary nutrition for neurological disease therapy: current status and future directions. Pharmacol Ther 226:107861. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107861","journal-title":"Pharmacol Ther"},{"key":"712_CR68","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1039\/d0fo00971g","volume":"11","author":"Z Yu","year":"2020","unstructured":"Yu Z, Ji H, Shen J, Kan R, Zhao W, Li J et al (2020) Identification and molecular docking study of fish roe-derived peptides as potent BACE 1, AChE, and BChE inhibitors. Food Funct 11:6643\u20136651. https:\/\/doi.org\/10.1039\/d0fo00971g","journal-title":"Food Funct"},{"key":"712_CR69","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/jsfa.10295","volume":"100","author":"Z Yu","year":"2020","unstructured":"Yu Z, Dong W, Wu S, Shen J, Zhao W, Ding L et al (2020) Identification of ovalbumin-derived peptides as multi-target inhibitors of AChE, BChE, and BACE1. J Sci Food Agric 100:2648\u20132655. https:\/\/doi.org\/10.1002\/jsfa.10295","journal-title":"J Sci Food Agric"},{"key":"712_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib11010001","volume":"11","author":"I Mahmood","year":"2022","unstructured":"Mahmood I, Pettinato M (2022) Impact of intrinsic and extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted? Antibodies 11:1\u201321. https:\/\/doi.org\/10.3390\/antib11010001","journal-title":"Antibodies"},{"key":"712_CR71","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1039\/d1fo01177d","volume":"12","author":"SS El-Hawary","year":"2021","unstructured":"El-Hawary SS, Sayed AM, Issa MY, Ebrahim HS, Alaaeldin R, Elrehany MA et al (2021) Anti-Alzheimer chemical constituents of: Morus macroura Miq.: chemical profiling, in silico and in vitro investigations. Food Funct 12:8078\u20138089. https:\/\/doi.org\/10.1039\/d1fo01177d","journal-title":"Food Funct"},{"key":"712_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26175124","volume":"26","author":"S Galati","year":"2021","unstructured":"Galati S, Di Stefano M, Martinelli E, Poli G, Tuccinardi T (2021) Recent advances in in silico target fishing. Molecules 26:1\u201318. https:\/\/doi.org\/10.3390\/molecules26175124","journal-title":"Molecules"},{"key":"712_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156108","author":"K Bhanukiran","year":"2024","unstructured":"Bhanukiran K, Priya V (2024) Exploring multitarget potential of Piper nigrum fruit constituents for Alzheimer\u2019s disease: an AI-driven strategy. Phytomedicine. https:\/\/doi.org\/10.1016\/j.phymed.2024.156108","journal-title":"Phytomedicine"},{"key":"712_CR74","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1021\/acschemneuro.3c00269","volume":"14","author":"K Bhanukiran","year":"2023","unstructured":"Bhanukiran K, Singh SK, Singh R, Kumar A, Hemalatha S (2023) Discovery of multitarget-directed ligands from piperidine alkaloid piperine as a cap group for the management of Alzheimer\u2019s disease. ACS Chem Neurosci 14:2743\u20132760. https:\/\/doi.org\/10.1021\/acschemneuro.3c00269","journal-title":"ACS Chem Neurosci"},{"key":"712_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2025.106355","volume":"68","author":"MI Kazeem","year":"2025","unstructured":"Kazeem MI, Abdulsalam RA, Mellem JJ, Sabiu S (2025) Lemongrass (Cymbopogon citratus) infusions exhibit neuroprotective properties: evidence from in vitro and in silico studies. Food Biosci 68:106355. https:\/\/doi.org\/10.1016\/j.fbio.2025.106355","journal-title":"Food Biosci"},{"key":"712_CR76","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2174\/0115672050358848241211080546","volume":"21","author":"K Bhattacharya","year":"2024","unstructured":"Bhattacharya K, Sungoh D, Kharmujai D, Islam A, Das D, Jha SK et al (2024) Exploring the therapeutic potential of 8-Prenyldaidzein: a comprehensive study of its multi-target efficacy in Alzheimer\u2019s Disease. Curr Alzheimer Res 21:578\u2013598. https:\/\/doi.org\/10.2174\/0115672050358848241211080546","journal-title":"Curr Alzheimer Res"},{"key":"712_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0313411","author":"FZ Guerguer","year":"2025","unstructured":"Guerguer FZ, Bouribab A, Karim EM, Khedraoui M, Amegrissi F, Raouf YS et al (2025) Moroccan natural products for multitarget-based treatment of Alzheimer\u2019s disease: a computational study. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0313411","journal-title":"PLoS ONE"},{"key":"712_CR78","doi-asserted-by":"publisher","first-page":"38118","DOI":"10.1021\/acsomega.3c04261","volume":"8","author":"S Srivastava","year":"2023","unstructured":"Srivastava S, Sharma S, Deep S, Khare SK (2023) Screening of multitarget-directed natural compounds as drug candidates for Alzheimer\u2019s disease using in silico techniques: their extraction and in vitro validation. ACS Omega 8:38118\u201338129. https:\/\/doi.org\/10.1021\/acsomega.3c04261","journal-title":"ACS Omega"},{"key":"712_CR79","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/cmdc.201900622","volume":"15","author":"GP Costa","year":"2020","unstructured":"Costa GP, Baldinotti RSM, Fronza MG, Nascimento JER, Dias \u00cdFC, Sonego MS et al (2020) Synthesis, molecular docking, and preliminary evaluation of 2-(1,2,3-triazoyl)benzaldehydes as multifunctional agents for the treatment of Alzheimer\u2019s disease. ChemMedChem 15:610\u2013622. https:\/\/doi.org\/10.1002\/cmdc.201900622","journal-title":"ChemMedChem"},{"key":"712_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269129","volume":"17","author":"IDG Mar\u00edn","year":"2022","unstructured":"Mar\u00edn IDG, L\u00f3pez RHC, Mart\u00ednez OA, Padilla-Mart\u00ednez II, Correa-Basurto J, Rosales-Hern\u00e1ndez MC (2022) New compounds from heterocyclic amines scaffold with multitarget inhibitory activity on A\u03b2 aggregation, AChE, and BACE1 in the Alzheimer disease. PLoS ONE 17:e0269129. https:\/\/doi.org\/10.1371\/journal.pone.0269129","journal-title":"PLoS ONE"},{"key":"712_CR81","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cbi.2006.12.006","volume":"171","author":"IM Kapetanovic","year":"2008","unstructured":"Kapetanovic IM (2008) Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 171:165\u2013176. https:\/\/doi.org\/10.1016\/j.cbi.2006.12.006","journal-title":"Chem Biol Interact"},{"key":"712_CR82","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ejmech.2019.02.030","volume":"167","author":"P Sharma","year":"2019","unstructured":"Sharma P, Tripathi A, Tripathi PN, Prajapati SK, Seth A, Tripathi MK et al (2019) Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 167:510\u2013524. https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.030","journal-title":"Eur J Med Chem"},{"key":"712_CR83","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1021\/acschemneuro.9b00430","volume":"10","author":"P Sharma","year":"2019","unstructured":"Sharma P, Tripathi A, Tripathi PN, Singh SS, Singh SP, Shrivastava SK (2019) Novel molecular hybrids of N-benzylpiperidine and 1,3,4-oxadiazole as multitargeted therapeutics to treat Alzheimer\u2019s disease. ACS Chem Neurosci 10:4361\u20134384. https:\/\/doi.org\/10.1021\/acschemneuro.9b00430","journal-title":"ACS Chem Neurosci"},{"key":"712_CR84","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1021\/acschemneuro.3c00653","volume":"15","author":"A Verma","year":"2024","unstructured":"Verma A, Waiker DK, Singh N, Roy A, Singh N, Saraf P et al (2024) Design, synthesis, and biological investigation of quinazoline derivatives as multitargeting therapeutics in Alzheimer\u2019s disease therapy. ACS Chem Neurosci 15:745\u2013771. https:\/\/doi.org\/10.1021\/acschemneuro.3c00653","journal-title":"ACS Chem Neurosci"},{"key":"712_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph16060880","volume":"16","author":"GO Mendes","year":"2023","unstructured":"Mendes GO, Pita SSdaR, Carvalho PBde, Silva MPda, Taranto AG, Leite FHA (2023) Molecular multi-target approach for human acetylcholinesterase, butyrylcholinesterase and \u03b2-secretase 1: next generation for Alzheimer\u2019s disease treatment. Pharmaceuticals 16:1\u201320. https:\/\/doi.org\/10.3390\/ph16060880","journal-title":"Pharmaceuticals"},{"key":"712_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121657","author":"DB Barbosa","year":"2023","unstructured":"Barbosa DB, do Bomfim MR, de Oliveira TA, da Silva AM, Taranto AG, Cruz JN et al (2023) Development of potential multi-target inhibitors for human cholinesterases and beta-secretase 1: a computational approach. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph16121657","journal-title":"Pharmaceuticals"},{"key":"712_CR87","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2174\/092986709789578213","volume":"16","author":"T Scior","year":"2009","unstructured":"Scior T, Medina-Franco J, Do Q-T, Martinez-Mayorga K, Yunes Rojas J, Bernard P (2009) How to recognize and workaround pitfalls in QSAR studies: a critical review. Curr Med Chem 16:4297\u20134313. https:\/\/doi.org\/10.2174\/092986709789578213","journal-title":"Curr Med Chem"},{"key":"712_CR88","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"A Cherkasov","year":"2014","unstructured":"Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M et al (2014) QSAR modeling: where have you been? Where are you going to? J Med Chem 57:4977\u20135010. https:\/\/doi.org\/10.1021\/jm4004285","journal-title":"J Med Chem"},{"key":"712_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25173916","volume":"25","author":"T-S Tran","year":"2020","unstructured":"Tran T-S, Le M-T, Nguyen T-C-V, Tran T-H, Tran T-D, Thai K-M (2020) Synthesis, in silico and in vitro evaluation for acetylcholinesterase and BACE-1 inhibitory activity of some N-substituted-4-phenothiazine-chalcones. Molecules 25:3916. https:\/\/doi.org\/10.3390\/molecules25173916","journal-title":"Molecules"},{"key":"712_CR90","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.3390\/molecules25163644","volume":"25","author":"T Tran","year":"2020","unstructured":"Tran T, Le M, Tran T, Tran T-H, Trai K-M (2020) Design of curcumin and flavonoid derivatives with acetylcholinesterase and beta-secretase inhibitory activities using in silico approaches. Molecules 25:3644. https:\/\/doi.org\/10.3390\/molecules25163644","journal-title":"Molecules"},{"issue":"18","key":"712_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25184064","volume":"25","author":"TS Tran","year":"2020","unstructured":"Tran TS, Tran TD, Tran TH, Mai TT, Nguyen NL, Thai KM, Le M-T (2020) Synthesis, in silico and in vitro evaluation of some flavone derivatives for Acetylcholinesterase and BACE-1 inhibitory activity. Molecules 25(18):4064. https:\/\/doi.org\/10.3390\/molecules25184064","journal-title":"Molecules"},{"key":"712_CR92","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.3390\/molecules25081846","volume":"25","author":"L Ivanova","year":"2020","unstructured":"Ivanova L, Karelson M, Dobchev DA (2020) Multitarget approach to drug candidates against Alzheimer\u2019s disease related to ACHE, SERT, BACE1 and GSK3\u03b2 protein targets. Molecules 25:1846. https:\/\/doi.org\/10.3390\/molecules25081846","journal-title":"Molecules"},{"key":"712_CR93","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-021-10282-8","author":"G Dhamodharan","year":"2021","unstructured":"Dhamodharan G, Mohan CG (2021) Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer\u2019s disease. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-021-10282-8","journal-title":"Mol Divers"},{"key":"712_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113098","author":"N Stern","year":"2022","unstructured":"Stern N, Gacs A, T\u00e1trai E, Flachner B, Hajd\u00fa I, Dobi K et al (2022) Dual inhibitors of AChE and BACE-1 for reducing A\u03b2 in Alzheimer\u2019s disease: from in silico to in vivo. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232113098","journal-title":"Int J Mol Sci"},{"key":"712_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemolab.2022.104734","volume":"233","author":"V Kumar","year":"2023","unstructured":"Kumar V, Saha A, Roy K (2023) Multi-target QSAR modeling for the identification of novel inhibitors against Alzheimer\u2019s disease. Chemom Intell Lab Syst 233:104734. https:\/\/doi.org\/10.1016\/j.chemolab.2022.104734","journal-title":"Chemom Intell Lab Syst"},{"key":"712_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemolab.2023.105049","volume":"245","author":"V Kumar","year":"2024","unstructured":"Kumar V, Banerjee A, Roy K (2024) Machine learning-based q-RASAR approach for the in silico identification of novel multi-target inhibitors against Alzheimer\u2019s disease. Chemom Intell Lab Syst 245:105049. https:\/\/doi.org\/10.1016\/j.chemolab.2023.105049","journal-title":"Chemom Intell Lab Syst"},{"key":"712_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28083588","author":"LQ Bao","year":"2023","unstructured":"Bao LQ, Baecker D, Mai Dung DT, Phuong Nhung N, Thi Thuan N, Nguyen PL et al (2023) Development of activity rules and chemical fragment design for in silico discovery of AChE and BACE1 dual inhibitors against Alzheimer\u2019s disease. Molecules. https:\/\/doi.org\/10.3390\/molecules28083588","journal-title":"Molecules"},{"key":"712_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00726","author":"F Wu","year":"2020","unstructured":"Wu F, Zhou Y, Li L, Shen X, Chen G, Wang X et al (2020) Computational approaches in preclinical studies on drug discovery and development. Front Chem. https:\/\/doi.org\/10.3389\/fchem.2020.00726","journal-title":"Front Chem"},{"key":"712_CR99","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/jcb.30483","volume":"124","author":"RAda Concei\u00e7\u00e3o","year":"2023","unstructured":"Concei\u00e7\u00e3o RAda, von Ranke N, Azevedo L, Franco D, Nadur NF, Kummerle AE et al (2023) Structure-based design of new N-benzyl-piperidine derivatives as multitarget-directed AChE\/BuChE inhibitors for Alzheimer\u2019s disease. J Cell Biochem 124:1734\u20131748. https:\/\/doi.org\/10.1002\/jcb.30483","journal-title":"J Cell Biochem"},{"key":"712_CR100","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.ejmech.2018.03.047","volume":"150","author":"MVPP Mello","year":"2018","unstructured":"Mello MVPP, Abrahim-Vieira BA, Domingos TFS, Jesus JB, Sousa ACC, Rodrigues CR et al (2018) A comprehensive review of chalcone derivatives as antileishmanial agents. Eur J Med Chem 150:920\u2013929. https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.047","journal-title":"Eur J Med Chem"},{"key":"712_CR101","first-page":"21","volume":"1107","author":"E Benfenati","year":"2013","unstructured":"Benfenati E, Manganaro A, Gini G (2013) VEGA-QSAR: AI inside a platform for predictive toxicology. CEUR Workshop Proc 1107:21\u201328","journal-title":"CEUR Workshop Proc"},{"key":"712_CR102","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/10937404.2019.1643539","volume":"22","author":"N Birkett","year":"2019","unstructured":"Birkett N, Al-Zoughool M, Bird M, Baan RA, Zielinski J, Krewski D (2019) Overview of biological mechanisms of human carcinogens. J Toxicol Environ Health B Crit Rev 22:288\u2013359. https:\/\/doi.org\/10.1080\/10937404.2019.1643539","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"712_CR103","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.2174\/138161205774414510","volume":"11","author":"D Schuster","year":"2005","unstructured":"Schuster D, Laggner C, Langer T (2005) Why drugs fail\u2013a study on side effects in new chemical entities. Curr Pharm Des 11:3545\u20133559. https:\/\/doi.org\/10.2174\/138161205774414510","journal-title":"Curr Pharm Des"},{"key":"712_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20455\/ros.2016.803","volume":"1","author":"R Li","year":"2016","unstructured":"Li R, Jia Z, Trush MA (2016) Defining ROS in biology and medicine. React Oxyg Species 1:9\u201321. https:\/\/doi.org\/10.20455\/ros.2016.803","journal-title":"React Oxyg Species"},{"key":"712_CR105","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/01614940.2020.1823788","volume":"64","author":"BRK Menon","year":"2022","unstructured":"Menon BRK, Richmond D, Menon N (2022) Halogenases for biosynthetic pathway engineering: toward new routes to naturals and non-naturals. Catal Rev Sci Eng 64:533\u2013591. https:\/\/doi.org\/10.1080\/01614940.2020.1823788","journal-title":"Catal Rev Sci Eng"},{"key":"712_CR106","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.drudis.2019.11.005","volume":"25","author":"MM Cavalluzzi","year":"2020","unstructured":"Cavalluzzi MM, Imbrici P, Gualdani R, Stefanachi A, Mangiatordi GF, Lentini G et al (2020) Human ether-\u00e0-go-go-related potassium channel: exploring SAR to improve drug design. Drug Discov Today 25:344\u2013366. https:\/\/doi.org\/10.1016\/j.drudis.2019.11.005","journal-title":"Drug Discov Today"},{"key":"712_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112290","volume":"195","author":"A Garrido","year":"2020","unstructured":"Garrido A, Lepailleur A, Mignani SM, Dallemagne P, Rochais C (2020) hERG toxicity assessment: useful guidelines for drug design. Eur J Med Chem 195:112290. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112290","journal-title":"Eur J Med Chem"},{"key":"712_CR108","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","volume":"18","author":"J Vamathevan","year":"2019","unstructured":"Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G et al (2019) Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 18:463\u2013477. https:\/\/doi.org\/10.1038\/s41573-019-0024-5","journal-title":"Nat Rev Drug Discov"},{"key":"712_CR109","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1021\/acs.jctc.3c00214","volume":"19","author":"J Zhang","year":"2023","unstructured":"Zhang J, Chen D, Xia Y, Huang Y-P, Lin X, Han X et al (2023) Artificial intelligence enhanced molecular simulations. J Chem Theory Comput 19:4338\u20134350. https:\/\/doi.org\/10.1021\/acs.jctc.3c00214","journal-title":"J Chem Theory Comput"},{"key":"712_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52061-7","author":"G Zhou","year":"2024","unstructured":"Zhou G, Rusnac DV, Park H, Canzani D, Nguyen HM, Stewart L et al (2024) An artificial intelligence accelerated virtual screening platform for drug discovery. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-024-52061-7","journal-title":"Nat Commun"},{"key":"712_CR111","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00044-024-03253-9","volume":"33","author":"AA Fadahunsi","year":"2024","unstructured":"Fadahunsi AA, Uzoeto HO, Okoro NO, Cosmas S, Durojaye OA, Odiba AS (2024) Revolutionizing drug discovery: an AI-powered transformation of molecular docking. Med Chem Res 33:2187\u20132203. https:\/\/doi.org\/10.1007\/s00044-024-03253-9","journal-title":"Med Chem Res"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00712-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:52:44Z","timestamp":1764730364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00712-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00712-2","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"7"}}